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Identifying active vascular microcalciﬁcation
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Vascular calciﬁcation is a complex biological process that is a hallmark of atherosclerosis.
While macrocalciﬁcation confers plaque stability, microcalciﬁcation is a key feature of high-
risk atheroma and is associated with increased morbidity and mortality. Positron emission
tomography and X-ray computed tomography (PET/CT) imaging of atherosclerosis using
18F-sodium ﬂuoride (18F-NaF) has the potential to identify pathologically high-risk nascent
microcalciﬁcation. However, the precise molecular mechanism of 18F-NaF vascular uptake is
still unknown. Here we use electron microscopy, autoradiography, histology and preclinical
and clinical PET/CT to analyse 18F-NaF binding. We show that 18F-NaF adsorbs to calciﬁed
deposits within plaque with high afﬁnity and is selective and speciﬁc. 18F-NaF PET/CT
imaging can distinguish between areas of macro- and microcalciﬁcation. This is the only
currently available clinical imaging platform that can non-invasively detect microcalciﬁcation
in active unstable atherosclerosis. The use of 18F-NaF may foster new approaches to
developing treatments for vascular calciﬁcation.
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V
ascular calciﬁcation is a complex pathological process
pathognomonic of atherosclerosis1–4. Currently, the
extent of macroscopic calciﬁcation can be determined by
X-ray computed tomography (CT) imaging and this can be used
clinically to predict cardiovascular morbidity and mortality5–7.
Vessel mineralization is ﬁrst marked by the appearance of
calciﬁed micro nodules which grow and coalesce into much larger
macroscopic deposits8. The genesis of these micro nodules is
principally mediated by a coordinated cellular pathway that
shares similarities to active skeletal osteogenesis but may also
involve a more passive process where a combination of high local
concentrations of phosphates and phosphatidylserines from
necrotic cells and an absence of calciﬁcation inhibitors results
in the precipitation of calcium phosphate particles. It is likely that
much of the mineral present is made up of hydroxyapatite, a
crystalline form of calcium orthophosphate9,10. Although there is
no universal size convention, emerging consensus categorizes
micro- and macrocalciﬁcation based on nodules of o50 and
Z50 mm, respectively11. This distinction is important because
although macrocalciﬁcation imparts plaque stability,
microcalciﬁcation heralds the onset of vessel mineralization
triggered by cell death and inﬂammation8,12 and may itself be
implicated in the aetiology of plaque rupture and major adverse
cardiovascular events13,14. Detection of microcalciﬁcation is not
possible with clinical CT systems that can only identify large areas
of macrocalciﬁcation—B200–500 mm in diameter10,15–17.
Furthermore, the rapid progression of existing vascular calcium
is driven by on-going microcalciﬁcation, carries a poor prognosis
and is not amenable to current medical therapies. As a
consequence, the development of techniques to identify
microcalciﬁcation is a major research goal with the potential for
improving patient risk stratiﬁcation and outcomes.
Positron emission tomography (PET)/CT imaging of athero-
sclerosis using 18F-sodium ﬂuoride (18F-NaF) has recently been
reported and, for the ﬁrst time, has the potential to non-invasively
identify high-risk microcalciﬁcation18–21. In patients with stable
coronary artery disease, 18F-NaF uptake correlates with CT
coronary calcium scores although nearly half of the patients with
very high scores have no 18F-NaF uptake and increased 18F-NaF
uptake is often seen in the absence of calciﬁcation on CT. 18F-
NaF would therefore appear to provide distinct information to
CT with potentially important clinical implications20. Recently,
we have shown that 18F-NaF uptake identiﬁes culprit ruptured
coronary plaques after myocardial infarction and, in carotid
plaque, correlates with markers of active calciﬁcation and cell
death21. Moreover, 18F-NaF appears to identify high-risk
coronary lesions in stable patients indicating that it may have a
role in identifying vulnerable plaques at risk of rupture and in
predicting myocardial infarction. In bone imaging, 18F-NaF
uptake involves the exchange of ﬂuoride ions with hydroxyl
groups in hydroxyapatite22,23; however, the mechanism
underlying 18F-NaF uptake in the vasculature has not been
established. This is a major limitation that must be addressed
before the nascent ﬁeld of vascular 18F-NaF PET imaging can
progress.
The goal of the study was to characterize the selectivity,
speciﬁcity and pharmacodynamics of 18F-NaF uptake in vascular
tissue in the human carotid atherosclerotic plaque. First,
we performed electron probe X-ray microanalysis to measure
18F-NaF presence directly in the areas of calciﬁcation
identiﬁed by electron microscopy. Second, we studied
the pharmacodynamic properties of 18F-NaF adsorption to
vascular calciﬁcation to characterize its potential as a clinical
imaging agent. We correlated the extent of 18F-NaF adsorption to
vascular calciﬁcation and to cell-speciﬁc markers of athero-
sclerosis to exclude the possibility of 18F-NaF binding to markers
of inﬂammation, neovascularization and smooth muscle cells as
opposed to solely calciﬁed deposits. We next compared the ability
of 18F-NaF to penetrate carotid micro- and macrocalciﬁcations
using high-resolution phosphor-imaging autoradiography and
light microscopy to understand 18F-NaF-binding properties to
these different forms of vascular calciﬁcations. Finally, we
compared clinical 18F-NaF PET/CT images with mPET/mCT
images of excised carotid endarterectomy specimens to develop a
translational model of 18F-NaF vascular uptake from bedside to
bench and back and understand 18F-NaF adsorption to vascular
calciﬁcation on all three levels studied.
We propose a comprehensive translational model of 18F-NaF
pharmacological characteristics to vascular calciﬁcation in pre-
clinical and clinical imaging systems. We conclude that 18F-NaF
PET/CT is the only currently available non-invasive clinical
imaging platform that can detect microcalciﬁcation in active
unstable human atherosclerosis.
Results
Electron microscopy analysis. We used an electron microprobe
to measure directly the presence of non-radioactive ﬂuoride
within calciﬁed and soft tissue areas of carotid endarterectomy
specimens. We also used hydroxyapatite standards to conﬁrm co-
localization (see Supplementary Table 1). When tissues were
preincubated with NaF, an energy-dispersive X-ray spectroscopic
peak for ﬂuoride was detectable and co-localized with regions of
calciﬁcation (Fig. 1a). Microcalciﬁcations showed greater levels of
ﬂuoride than macrocalciﬁcations (F/Ca ratio: 0.59±0.23 (n¼ 10,
individual plaques) versus 0.37±0.15 (n¼ 7, individual plaques),
respectively, Po0.02, ANOVA (analysis of variance) and Tukey
Kramer post hoc test, Fig. 1b) and no tissue ﬂuoride was observed
in the absence of calciﬁcation (Fig. 1c). Thus, at the resolution of
electron microscopy, ﬂuoride co-localized to arterial calciﬁcation,
with increased levels in the regions of microcalciﬁcation.
Pharmacodynamic and pharmacokinetic analyses. To conﬁrm
the speciﬁcity in pharmacological assays, we incubated carotid
sections with a clinically relevant concentration (1 10 11M) of
18F-NaF for 1 h (ref. 21). As a control for nonspeciﬁc binding,
adjacent sections were incubated at the same concentration of
18F-NaF, but with an excess (4 10 4M) of non-radioactive
NaF. Phosphor-imaging autoradiography revealed a strong
18F-NaF signal with negligible nonspeciﬁc binding and no
18F-NaF binding in areas without calciﬁcation (Supplementary
Fig. 1). Concentration–response curves were constructed by
exposing carotid sections (n¼ 5) to increasing concentrations of
18F-NaF (10 12–10 7M) for 1 h (refs 20,23). There was a
positive linear correlation between the radioactivity and
concentration of 18F-NaF (Fig. 1d). We then performed asso-
ciation and dissociation binding experiments at a clinically rele-
vant concentration (1 10 11M; n¼ 5). There was a rapid and
time-dependent exponential association and, following washing, a
slow exponential dissociation from the plaque (Fig. 1e). The data
were ﬁtted to a one-site model, with an association rate constant
(k1) of 4.5±0.6 109M 1min 1 and a half-time for asso-
ciation of 14.3±1.9min. Dissociation was slow but detectable
with a dissociation rate constant of 0.0027±0.0005min 1, a
half-time for dissociation of 254±43min and an afﬁnity constant
(KD) calculated from these kinetic data of 0.6 pM. The afﬁnity
constant is a measure of the strength of binding of 18F-NaF to
areas of calciﬁcation. The very high afﬁnity is consistent with the
comparatively low concentrations of radiolabelled 18F-NaF
required in vitro and in vivo to detect calciﬁcations in tissues and
demonstrates the sensitivity of the tracer.
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We undertook dynamic PET analysis to explore the in vivo
pharmacodynamic and pharmacokinetic properties of 18F-NaF in
ﬁve patients scheduled to undergo carotid endarterectomy for
symptomatic disease (patient demographics both for dynamic
scans and static scans described later are given in Supplementary
Table 2. The SUV and TBR values of static and dynamic scans in
table format are given in Supplementary Table 3 and in graphical
format in Supplementary Fig. 2). There was clear carotid plaque
uptake and Patlak analysis showed a good model ﬁt with 18F-NaF
inﬂux varying from 0.0005 to 0.007ml cm 3min 1 as compared
with 0.05 to 0.08ml cm 3min 1 in the vertebral bodies
(Supplementary Table 4 and Supplementary Fig. 3). No deviation
of the data from the model was observed during the time course
of these experiments although patients could only tolerate
scanning for 75min following tracer injection. Although very
slow dissociation can be detected in vitro, this was too slow to
detect during our imaging window in vivo and therefore is
unlikely to be an important factor to take into account in clinical
imaging. 18F-NaF was rapidly eliminated from the plasma and
showed a typical biexponential decay in keeping with immediate
redistribution and then subsequent renal elimination
(Supplementary Fig. 4). At 60min from injection, plasma activity
was 4–8% of its peak activity and excellent contrast between
vascular tissue and blood pool was observed.
These complementary ex vivo and in vivo data demonstrate the
favourable imaging properties of 18F-NaF: an absence of
metabolites, rapid ligand-binding site association with minimal
dissociation and a rapid reduction in radiotracer background
giving excellent tissue contrast resolution 1 h following its
administration.
Immunohistochemical analysis. Vascular calciﬁcation is believed
to occur in response to hypoxia, necrosis and chronic inﬂam-
mation and has been linked with macrophage burden and neo-
vascularization3. To test the cellular speciﬁcity of 18F-NaF
binding, we stained sequential sections with Alizarin Red
(calciﬁcation marker) and antibodies for CD68 (macrophage
marker), CD31 (endothelial cell marker of neovascularization)
and smooth muscle actin (smooth muscle marker; n¼ 8
keV
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Figure 1 | F directly co-localizes with Ca in a concentration-dependent manner. (a) Fluoride peak is detected only in the calciﬁed regions of those carotids
that have been exposed to NaF. (b) The amount of ﬂuoride adsorbed to microcalciﬁcations (identiﬁed visually based on the size of nodules of o50 and
manual measurements made) is signiﬁcantly higher than macrocalciﬁcations (Z50mm to several mm; F/Ca in microcalciﬁcations 0.59±0.23, n¼ 10
(circles); in macrocalciﬁcations 0.37±0.15, n¼ 7 (squares)); Po0.02 using an ANOVA and Tukey Kramer post hoc test. (c) Representative images of
macro- and microcalciﬁcations and the soft tissue. F presence was detected only in the calciﬁed regions. Scale bar, 50mm. (d) 18F-NaF binding to cryostat
sections is linear over the clinically relevant concentration range from 1.0 10 12 to 1.0 10 7 (y¼ 10(0.92*log(x)þ 13), n¼ 5). (e) There is a fast
exponential association and slow exponential dissociation of 18F-NaF to the whole carotids over time. In all ﬁgures ﬁlled shapes show mean, error bars
denote s.e.m.
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individual plaques for each stain). We then ﬁltered and applied an
auto-threshold to both the 18F-NaF radioactivity signal and each
of the histological stains, and overlaid them to correlate the two
signals (Fig. 2a). The only high correlation detected was between
the 18F-NaF signal and Alizarin Red calciﬁcation stain
(r¼ 0.69±0.03, n¼ 8) indicating that 18F-NaF speciﬁcally co-
localizes to vascular calciﬁcation and not other upstream triggers
to the calciﬁc response (Fig. 2b).
Penetration by autoradiography/histology and lPET/lCT. We
next compared areas of 18F-NaF uptake with tissue micro- and
macrocalciﬁcation. We ﬁrst sectioned carotid plaques to remove
barriers to penetration and incubated with 1 10 11M 18F-NaF
for 1 h, followed by exposure to a phosphor-imaging screen. 18F-
NaF uptake correlated with calciﬁcation staining (Fig. 3a, mac-
rocalciﬁcations: closed arrowheads, microcalciﬁcations: open
arrowheads) and was observed across all regions of the calciﬁc
deposits (Fig. 3b). In contrast, if carotids were ﬁrst incubated with
18F-NaF and then sectioned, 18F-NaF binding was only detected
on the outer surface layer of macrocalciﬁc deposits with the
ligand unable to penetrate deeper (Fig. 3c,d, and Supplementary
Fig. 5 for additional examples). Irrespective of presectioning of
tissue, 18F-NaF appeared to bind freely to regions of micro-
calciﬁcation and co-localized with histological staining for calci-
ﬁcation (Fig. 3a–d). Using mPET/mCT, we saw similar results with
18F-NaF binding only to the surface of macrocalciﬁc deposits
(Fig. 3e,f), matching the limits of penetration demonstrated with
autoradiography.
One of the main aims of this work was to explain the
previously observed differences between the PET and CT signals
in the clinical setting. We chose to investigate this using
preclinical mPET/mCT because of the higher spatial resolution
that it offers (mPET, 900 mm; mCT, 30 mm). We hypothesized that
the use of higher-resolution mPET/mCT would allow detection of
microcalciﬁcations. While microcalciﬁcations identiﬁed on his-
tology (Fig. 3g) were not detectable by mCT (Fig. 3i), they were
identiﬁed by an increased 18F-NaF mPET signal (Fig. 3j) that
closely matched phosphor-imaging autoradiography (Fig. 3h).
Finally, we further investigated 18F-NaF penetration by examin-
ing the intensity and density of the mPET and mCT signals (where
calciﬁcation was deﬁned asZ1,000 Hounsﬁeld units (HU)) along
5–8-mm linear transects of atherosclerotic tissue (Fig. 3k–o).
Once again there were clear differences in the signal produced by
these two imaging techniques with increased 18F-NaF activity on
the surface of macroscopic calcium deposits that by contrast was
not observed within their core.
Comparing clinical in vivo PET/CT and ex vivo lPET/lCT.
We applied a novel approach to compare the in vivo and
ex vivo imaging of carotid atherosclerotic plaque using
co-registered clinical PET with CT, mPET with mCT and
autoradiography with histology. In particular, we focused on the
mismatch between the 18F-NaF PET signal and CT identiﬁable
calciﬁcation (Fig. 4).
We recruited four patients who were scanned with 18F-NaF
PET/CT before carotid endarterectomy (Fig. 4a). After surgery,
we incubated the endarterectomy specimens with 18F-NaF and
imaged them with the mPET/mCT scanner (Fig. 4h). Finally,
we again incubated the carotid endarterectomy specimens with
18F-NaF and cryosectioned them to obtain autoradiography
images and light microscope histology to detect areas of calcium
(Fig. 4n). On the clinical PET/CT and mPET/mCT scans, we
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conﬁrmed differences in the distribution of calcium on CT and
18F-NaF uptake on PET (Fig. 4c–g, for Fig. 4e–g corresponding
three-dimensional (3D) Supplementary Movies 1–3). Regions of
18F-NaF uptake were most commonly observed in the absence
of calcium on CT, representing areas of microcalciﬁcation (PETþ /
CT ; Fig. 4b,i). In addition, there were also large CT-detected
areas of macrocalciﬁcation that did not demonstrate concomitant
18F-NaF uptake (PET /CTþ ; Fig. 4b,g (for Fig. 4g, correspond-
ing 3D Supplementary Movie 3)). These are likely to represent
regions where nascent microcalciﬁcation is mild or absent.
The ﬁndings on mPET/mCT were similar to the clinical scans.
Indeed the distribution of calcium detected with mCT closely
matched that observed on the clinical CT although additional
smaller areas of macrocalciﬁcation were also identiﬁed and resolved
(Fig. 4j–m, corresponding 3D Supplementary Movies 4–7). The
distribution of the 18F-NaF signal was also similar although again it
was more reﬁned on the mPET compared with the clinical PET
systems (Fig. 4j–l, corresponding 3D Supplementary Movies 4–6).
Finally, histology and 18F-NaF autoradiography provided the most
sensitive method for the detection of tissue calciﬁcation (Fig. 4o–u).
Histological staining with Alizarin Red conﬁrmed that both mCT
and clinical CT only detect regions of macrocalciﬁcation with
extensive regions of microcalciﬁcation left unresolved by these
techniques (Fig. 4p–u). By contrast, the 18F-NaF signal detected by
autoradiography was observed in a very similar distribution to that
observed by the mPET (albeit providing better spatial resolution),
with both able to resolve regions of microcalciﬁcation (Fig. 4r–u).
For the number of patients used in the individual experiments, see
Supplementary Table 5.
Discussion
For the ﬁrst time, we demonstrate the speciﬁcity and sensitivity of
18F-NaF adsorption to calcium deposits in human atherosclerotic
vascular tissue and demonstrate that it can non-invasively detect
areas of microcalciﬁcation indicative of nascent calciﬁcation and
a
b
c
H
is
to
lo
gy
Au
to
ra
di
og
ra
ph
y
µCT
µPET
IntactSectioned Intact Intact Intact
d
e g i
m
n
k
o
l
0
8,000
16,000
0 2 4
CT
 
(H
U)
m
0
2
4
6
8x105
PET (Bq ml
–1)
0 2 4 6
n
0
2
4
6
8x105PET (Bq ml
–1)0
8,000
16,000
CT
 
(H
U)
40 2
0
2
4
6
8x105PET (Bq ml
–1)
Length (mm)
o
0
8,000
16,000
CT
 
(H
U)
Length (mm)
f h j
Figure 3 | 18F-NaF signal detection depends on the sensitivity of the detection modality. (a,b) If the carotid is sectioned ﬁrst and incubated in
18F-NaF second, binding occurs to all macro- (closed arrowheads) and microcalciﬁcation (open arrowheads) surfaces. (c,d) However, if the carotid is
incubated in 18F-NaF ﬁrst and then sectioned, 18F-NaF is able to bind only to the surface level of macrocalciﬁcations (closed arrowheads), while binding
occurs to all microcalciﬁcations (open arrowheads). (e,f) 18F-NaF binding solely to the surface level of macrocalciﬁcations can also be observed in a mPET/
mCTscan, if the macrocalciﬁcation size is larger than mPET resolution. (g,i) Microcalciﬁcations that are detected with Alizarin Red histology cannot be seen
in a mCT scan, due to insufﬁcient sensitivity. (h,j) Yet, 18F-NaF mPET scan closely matches autoradiography signal and can detect microcalciﬁcations.
(k,l) mPET/mCT signal quantiﬁcation by measuring the intensity of the 18F-NaF mPET signal and the mCT density measure along the same transects.
(m) 18F-NaF binding can be observed throughout the three macrocalciﬁcation peaks due to macrocalciﬁcation size being smaller than mPET resolution
(PETþ/CTþ , blue arrowheads); (n) Microcalciﬁcations detected with 18F-NaF mPETand autoradiography (see h) as well as Alizarin Red histology (see g)
but not mCT (PETþ/CT , magenta arrowheads); (o) If macrocalciﬁcations are larger than mPET resolution, 18F-NaF binding solely around the surface
level of macrocalciﬁcations can be observed, similarly as in autoradiography (center green arrowhead PET/CTþ , blue arrowheads PETþ/CTþ ).
Scale bar, 1mm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8495 ARTICLE
NATURE COMMUNICATIONS | 6:7495 | DOI: 10.1038/ncomms8495 | www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
active unstable atherosclerosis. This unique and characteristic
signal has implications and ramiﬁcations for the non-invasive
clinical imaging of human atherosclerosis—a condition that
represents the leading cause of death worldwide.
In bone, the binding of ﬂuoride to areas of calciﬁcation is
mediated through a chemical reaction with hydroxyapatite, a
crystalline structure that is also the main component of vascular
mineralization22. Using electron microprobe analysis, we have
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shown for the ﬁrst time that ﬂuoride also closely co-localizes to
pathological mineralization within vascular tissue. The precise
target for NaF binding in living vasculature has been uncertain, as
ﬂuoride ions were not expected to have the selectivity as seen
between ligands and their cognate receptors, and NaF could
target molecules other than hydroxyapatite. Here we demonstrate
that 18F-NaF co-localizes to areas of nascent calciﬁcation and
potentially provides a novel non-invasive biomarker of this high-
risk pathology. Moreover, we observed that there is preferential
adsorbing of ﬂuoride to microcalciﬁcation, a clinically more
signiﬁcant manifestation of vascular mineralization. The extent of
ﬂuoride adsorption depends on the surface area of the
mineral24,25 and would be consistent with the proposal that the
complex convex surface structure of microcalciﬁcations allows
more binding of ﬂuoride than the relatively ﬂat and smaller
surface area of macrocalciﬁcation.
The association and dissociation of 18F-NaF to carotid
endarterectomy specimens showed an exponential rise and decay
of signal, with excellent contrast between activity in vascular
tissue and the blood pool observed as early as 60min following
injection. Studies in artiﬁcial chemical models have shown that
ﬂuoride binding to hydroxyapatite also occurs in an exponential
binding reaction24,25 and can be explained both by physico- and
chemisorption24. This also appears as the most likely mechanism
in human carotids but it is important to emphasize that not all
calciﬁcation observed can be generalized to consist of
hydroxyapatite. Previous clinical radiology reports have
described an initial ﬂuoride-bound water shell entrapment and
a slow ion exchange22; however, no mechanistic studies to prove
these assumptions have been published, at least to our knowledge.
Therefore, we propose that our observations match the ﬁndings
in artiﬁcial systems and the ﬂuoride adsorption to hydroxyapatite
in whole-carotid sections can be explained by physico- and
chemisorption and the dissociation is a result of a washout,
similar to what has been described in artiﬁcial systems24.
The mechanism of early micronodular intimal atherosclerotic
calciﬁcation is not yet clearly understood although its genesis has
been linked to, amongst others factors, inﬂammatory macro-
phages, inﬂammatory lipids, apoptosis, neovascularization and
phenotypically altered vascular smooth muscle cells3. We have
demonstrated that 18F-NaF binds speciﬁcally and sensitively to
the ﬁnal common pathway of precipitated micro nodules of
pathological calciﬁcation (whether through active or passive
mechanisms) and not directly to any of these putative earlier
upstream triggers. This is in contrast to 18F-ﬂuorodexoyglucose,
which although linked to activated macrophages in the
vasculature, may lack sensitivity and speciﬁcity for identifying
inﬂammation speciﬁc activation26 and does not have the highly
favourable pharmacokinetics of 18F-NaF26,27.
The main question we sought to answer was why does the
18F-NaF clinical PET/CT imaging result in a signal mismatch
between the two modalities? Speciﬁcally, why do some areas of
macrocalciﬁcation show no uptake, while other areas without
apparent calciﬁcation show high 18F-NaF uptake? To address this,
we used carotid endarterectomy sections and compared ex vivo
and in vivo imaging approaches. Since vascular calciﬁcation
consists predominantly of mineral and only a small amount of soft
tissue, the architecture of the calciﬁcation in the in vivo and ex vivo
environments was very similar. Using autoradiography, we were
able to show that if the ex vivo carotid was ﬁrst incubated in
18F-NaF and then cryosectioned, 18F-NaF only bound to the outer
surface of the macrocalciﬁcations. In contrast, microcalciﬁcations
had a greater surface area and no barriers to penetration of the
tissues resulting in high levels of 18F-NaF adsorption. This
suggests that 18F-NaF cannot penetrate into the deeper layers of
macrocalciﬁcation. Since macrocalciﬁcations have a large volume
but small surface area, the detected radioactivity signal is
proportionally smaller than microcalciﬁcations with a small
volume and large surface area. Microcalciﬁcations are also
dispersed in large numbers per given area of the tissue, again
resulting in a disproportionally high signal compared with
macrocalciﬁcations. Furthermore, when sectioned carotid endar-
terectomy specimens were directly exposed to 18F-NaF, uptake
was this time observed also in the centre of macroscopic deposits
that had now been made accessible to the tracer. We therefore
conclude that the adsorption of 18F-NaF to areas of calciﬁcation in
carotid endarterectomy tissue is a measure of the available surface
area accessible to the isotope. This is consistent with ﬁndings in
the bone and explains the observed greater adsorption of 18F-NaF
to microcalciﬁcations (Fig. 5a,b).
mPET/mCT scans of ex vivo carotids and their comparison with
autoradiography revealed that mPET closely matches autoradio-
graphy. On the other hand, mCT was only able to detect
macrocalciﬁcations (Fig. 5c) and underestimated the extent of
vascular microcalciﬁcation identiﬁed by Alizarin Red histology.
Back-correlation of mPET/mCT ex vivo scans to clinical in vivo
PET/CT scans showed similar results. Using clinical CT, it was
possible to detect the larger macrocalciﬁcations, and their shape
closely matched the data acquired by mCT. In contrast, the 18F-
NaF uptake detected by the clinical and mPET co-localized with
both underlying calcium deposits (PETþ /CTþ ) and regions
with no apparent calciﬁcation (PETþ /CT ) as assessed on CT
(Fig. 5d). For the latter situation, our histological studies showed
that the PET signal was in fact binding to microcalciﬁcations
below the detection limit of clinical CT and mCT. We therefore
conclude that areas of 18F-NaF uptake are reporting underlying
microcalciﬁcations, which are undetectable by CT. Conversely,
large CT-detected macrocalciﬁcations that do not co-localize with
18F-NaF PET uptake (PET /CTþ ) might be considered to
represent dormant areas where on-going mineralization, as
evidenced by the presence of microcalciﬁcation, has ceased and
atherosclerotic disease is quiescent. Indeed, more heavily calciﬁed
plaques have been reported to be particularly prevalent in more
stable disease and are much less vulnerable to rupture28,29.
In summary, using electron microprobe analysis, we have
demonstrated for the ﬁrst time that ﬂuoride directly adsorbs to
calciﬁed areas in mineralized vascular tissue. We have shown that
binding is highly speciﬁc since 18F-NaF radioactivity is conﬁned
solely to calciﬁcation, with no localization to other soft tissues.
Furthermore, we observed that 18F-NaF signal is highly
dependent on the surface area of the calciﬁcation, being able to
adsorb only to the outer layer of macrocalciﬁcations without
deeper penetration. We replicated these ﬁndings on three levels—
autoradiography, light microscopy, in vivo clinical PET/CT and
ex vivo mPET/mCT. These characteristic position 18F-NaF as a
highly speciﬁc ligand for the detection of pathologically high-risk
microcalciﬁcation and early unstable atherosclerotic disease. 18F-
NaF is an economical PET ligand that is easy to manufacture. If
used clinically, 18F-NaF uptake has the potential to identify
microcalciﬁcation within high-risk plaques as well as determine
the locations of plaque rupture. In addition, as a marker of
nascent calciﬁcation, it could test the efﬁcacy of pharmacological
therapies targeting atherosclerosis or calciﬁcation in both the
clinical and preclinical settings. Microcalciﬁcations are also linked
to other disease processes, such as breast cancer, prostate cancer
and stroke. The main aim of this study was to understand the
molecular mechanisms of 18F-NaF uptake and not to deﬁne
patients at risk. With data validating its co-localization with
calciﬁcation, the potential now exists to evaluate these processes.
Whether or not 18F-NaF will be useful in stratifying risk of
cardiovascular events remains to be demonstrated. Large-scale
prospective investigations will be essential to determine the
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prognostic value for 18F-NaF role in risk stratiﬁcation. Never-
theless, 18F-NaF PET/CT holds promise and may have wide-
ranging applications and become a valuable clinical tool to study
active calciﬁcation across many disease areas and disciplines.
Methods
All chemicals were purchased form Sigma-Aldrich, Dorset, UK, unless stated
otherwise.
Human tissues. The atherosclerotic intimal layers of human carotid arteries
(further in text: carotids) were obtained with ethical approval and informed con-
sent after endarterectomy surgeries (National Health Service Local Research Ethics
Committee approval in Cambridge: 97/084, National Health Service West of
Scotland Research Ethics Committee approval in Edinburgh: 12/WS/0227). The
mean patient age was 71±2 years and both male and female patient carotids were
used. The tissue was collected immediately after the surgery and was fresh frozen
in  80 C. It was kept frozen until the start of the experimental procedures.
In clinical imaging, the concentration of the injected 18F-NaF in plasma was
calculated as approximately 1 10 11M. Initial experiments were performed both
on fresh carotids and carotids that had undergone a freeze-thaw cycle and no
differences in 18F binding were observed in terms of radioactivity penetration into
macrocalciﬁcations.
Electron microscopy. Frozen carotid tissue was placed in cryostat for 1 h to
equilibrate to  20 C temperature. It was then immersed in Optimal Cutting
Temperature compound (OCT) Embedding Matrix (CellPath, Powys, UK) and
30-mm thick, serial sections were cut on a Bright (Huntingdon, UK) cryostat.
Sections were placed on custom-made Melinex discs (diameter: 12mm) and
allowed to dry. Discs were then frozen in  80 C temperature until the day of
experiment. During the experiment, tissue sections were allowed to thaw and then
incubated with 120ml 0.01M non-radioactive NaF for 2 h at room temperature.
After incubation, sections were dipped in distilled H2O three times and allowed to
dry. The discs were stuck to 12.5mm Cambridge style scanning electron micro-
scope stubs and coated with carbon in an Edwards Auto 306 evaporative carbon
coater. They were imaged in an FEI XL30 FEGSEM operated at 20 kV with
secondary and backscattered electron detectors. Calciﬁcation was detected
predominantly in the regions of intimal thickening and was designated micro-
(spherical or near spherical deposits o50mm in diameter) or macrocalciﬁcation
(where large regions between 50 mm and several mm in size were calciﬁed).
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Figure 5 | Our model of 18F-NaF binding to the vascular calciﬁcations. (a) 18F-NaF highly speciﬁcally binds to both micro- and macrocalciﬁcations and
the signal strength depends on the available surface area of these calciﬁcations. (b) Schematic of histology/autoradiography vascular calciﬁcation
detection. Alizarin Red histology results in the most deﬁnitive delineation of calciﬁcation, with the detection limit into the nanometre range. Phosphor
screen autoradiography also has a much higher resolution compared with PET and mPET, resulting in accurate detection of calciﬁcations. (c) Schematic of
preclinical mPET/mCT vascular calciﬁcation detection. mCT detects macrocalciﬁcations and their ﬁner architecture. Proportionally less signal is detected on
mCT than using histology, yet more than the clinical CT. mPET very precisely detects both macro and microcalciﬁcations. In addition, if the macro-
calciﬁcations exceed mPET resolution, it is possible to observe 18F-NaF binding to the outer surface of macrocalciﬁcations. There are less PET/CTþ
regions observed than using autoradiography but more than clinical PET/CT. (d) Schematic of clinical PET/CT vascular calciﬁcation detection. Here CT is
able to detect gross macrocalciﬁcations and PET detects both CTþ and CT calciﬁcations. However, the signal is diffuse, resulting in much larger
and therefore less precise PETþ detections, as compared with the ex vivo imaging modalities described here.
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Both types of calciﬁcation were analysed by energy-dispersive X-ray micro-
analysis in 10 arteries. Spectra were collected using an Oxford Instruments
SiLi atmospheric thin window detector running INCA software (ETAS Group,
Stuttgart, Germany). Between 10 and 57 spectra were collected from both types
of calciﬁcation (where present) for 100 s live time. As a control to assess nonspeciﬁc
binding of F, spectra were also collected from regions of the arterial media
where no backscattered electron signal for hydroxyapatite was present. The spectra
were deconvolved in the INCA software and to estimate F/Ca only Ca and F
spectra were input into the analysis. The quantitative data were expressed as atomic
%. F/Ca was estimated by dividing the atomic % of F by the atomic % of Ca. Data
are presented as means±the s.e.m. and F/Ca between regions of micro- and
macrocalciﬁcation was compared using an ANOVA and Tukey Kramer post hoc
test.
Additional electron microscopy analysis was performed with commercial
hydroxyapatite standards. Hydroxyapatite (2mg) was incubated with 1ml of 1%
NaF on a rotator for 8 h or 4 days. The standards were then rinsed 10 times for
20min in distilled water and air dried onto coverslips. They were mounted onto
12.5mm Cambridge scanning electron microscope stubs, carbon coated and
analysed in the same way as the cryostat sections. Control samples of
hydroxyapatite standards were treated similarly as described above but the NaF
incubation step was omitted. The hydroxyapatite analysed in the cryostat section is
at least partially embedded/encapsulated in the tissue of the arteries and sections
were coated in the same way with carbon to make them electrically conductive. As
the carbon was added it was excluded from the analysis. Concentrations of O, P
and Ca in the control hydroxyapatite are expressed in atomic per cent.
In the NaF-treated hydroxyapatite, no signal for Na was seen after extensive
washes, and the concentrations of O, F, P and Ca were expressed as atomic per
cent. Despite extensive washing, a clear signal for F was retained, indicating
binding to the hydroxyapatite. In these control samples the interaction volume of
the electron beam is expected to remain within hydroxyapatite alone whereas in the
tissue sections a proportion of the interaction volume will also generate X-rays
from the surrounding arterial tissue. Therefore the ratio of F/Ca was used to
measure differences in F concentration between areas of macro- and micro-
calciﬁcation.
18F-NaF binding to cryostat cut carotid artery sections. For all experiments
18F-NaF was synthesized by the Wolfson Brain Imaging Centre (WBIC)
(Cambridge, UK). The typical activity was approximately 285MBq.
Frozen whole carotids were placed in the cryostat for 1 h to equilibrate to
 20 C temperature. Tissue was then immersed in the OCT Embedding Matrix
(CellPath, Powys, UK) and 20 mm thick, serial sections were cut on a Bright
(Huntingdon, UK) cryostat. Sections were allowed to dry in room temperature and
stored at  80 C temperature until the start of the experiment.
The concentration of 18F-NaF was detected using F electrode (Thermo
Scientiﬁc, Loughborough, UK) and was then diluted to 1 10 11M. For
nonspeciﬁc binding detection, 20 ml of 0.1M unlabelled NaF solution (Orion
Ionplus F Standard, Thermo Scientiﬁc, Loughborough, UK) were added to an
aliquot of the radioactive 1 10 11M solution. Frozen tissue sections were
allowed to thaw and washed with PBS for 10min in room temperature. Adjacent
sections were incubated either with 18F-NaF or 18F-NaF plus unlabelled NaF
solutions for 1 h at room temperature. They were then washed in PBS 3 5min
and dipped in distilled H2O. After drying, tissues were placed on a charged
phosphor screen (Perkin Elmer, Waltham, Massachusetts) and left overnight. The
following day screens were read using PerkinElmer’s Cyclone Plus Phosphor
Imager (Waltham, Massachusetts) and data were analysed with OptiQuant
software (Packard Instrument, Meriden, Connecticut). Areas of micro- and
macrocalciﬁcation were identiﬁed visually based on the size of nodules ofo50 and
Z50mm to several mm, respectively, and manual measurements made.
For concentration–response curve, the same method was used, except stock
18F-NaF solution was split into serial dilutions from 10 12 to 10 7M. After
washing in PBS and dipping in distilled H2O, tissues were wiped off the slides with
ﬁlter paper, which was put into radioimmunoassay tubes and measured in the
gamma counter (Packard Cobra II E5003, GMI, Ramsey, Minnesota).
18F-NaF binding in whole-carotid arteries. Whole-carotid arteries were thawed
in 5ml PBS for 1 h, and then placed in 5ml of 10 11M 18F-NaF solution for 1 h at
room temperature. They were then washed in PBS 3 2min, followed by a dip in
distilled H2O. Carotids were transferred to cryostat, immersed in OCT and allowed
to freeze. Tissue was then cut into 20-mm serial sections, which were allowed to dry
on microscopy slides. After drying, tissues were placed on a charged phosphor
screen and left overnight.
For whole-carotid association and dissociation binding curves, the same
method was used, except during association binding experiments, carotids were
taken out from the 5ml of 10 11M 18F-NaF tube at set time points—0, 5, 15, 30,
60min, washed and measured in the gamma counter. For dissociation binding
experiment, after the incubation in 5ml of 10 11M 18F-NaF for 1 h, tissues were
continuously washed in PBS for set amounts of time—0, 5, 10, 15, 30, 45, 60, 90,
120min. Instead of cryostat cutting, arteries were placed in radioimmunoassay
tubes and measured in the gamma counter.
Tissue staining. Tissue sections were cut on cryostat as described in section
‘18F-NaF binding to cryostat cut carotid artery sections‘.
Alizarin red staining. Alizarin Red staining (Alfa Aesar, Heysham, UK) was used
for calciﬁcation detection in carotid arteries. In brief, cryosections were left to dry
overnight. They were then ﬁxed in acetone for 10min at 4 C and washed in PBS
2 5min at room temperature. After washing, 300 ml Alizarin Red were applied to
each section for 1min. Tissue was then put in acetone for 1min, followed by a
wash in 50:50 acetone:xylene for 1min and then left in xylene for at least 1 h.
Immunohistochemistry. Immunohistochemistry was used to detect multiple
inﬂammatory tissue markers in cryosections. Tissue was left to dry overnight and
the following day it was ﬁxed in acetone at 4 C for 10min and washed in PBS
2 5min at room temperature. Sections were blocked in 10% goat serum for 1 h
and H2O2 for 5min. Each blocking step was followed by washing in PBS for
2 5min. Carotids were then incubated in primary antibody for 30min at room
temperature. Antibodies included CD68 (1:500, clone PG-M1), CD31 (1:20, clone
JC70A) and Smooth Muscle Actin (1:500, clone 1A4) (all from Dako UK, Ely, UK).
Labelled polymer-HRP anti-rabbit application and visualization with 3,30-diami-
nobenzidine (DAB) was done using EnVisionþ System-HRP (DAB) kit (Dako
UK, Ely, UK), following manufacturers speciﬁcations. Counterstain of 150 ml
haemotoxylin was applied to each section and incubated for 1min. Slide was then
dipped six times in destain solution (1% HCl, 50% methanol, 49% distilled H2O)
and washed in tap water for 2min. Afterwards tissue was quickly dehydrated in
1min intervals through graded alcohols (30 to 70% to 100% to absolute alcohol 1 to
absolute alcohol 2) and cleared in xylene for at least 1 h.
Section mounting. After staining, all tissues were mounted using DePeX
mounting medium Gurr (VWR, Lutterworth, UK) and glass coverslips (Menzel-
Gla¨ser, Braunschweig, Germany). After hardening of the mounting solution, tissues
were imaged using Wild Heerbrugg M3Z microscope (Leica, Heerbrugg,
Switzerland).
lPET/lCT imaging of whole-carotid arteries. Whole-carotid arteries were
removed from  80 C freezer and thawed in 5ml PBS at room temperature for
1 h. After thawing, tissues were placed in 1 10 9M 18F-NaF solution and
incubated for 1 h. Tissues were then washed in PBS 3 2min and dipped in
distilled water. They were then placed in sealed plastic tubes. Tissue radioactivity
was read using dose calibrator and they were then placed into the mPET/mCT
scanner. Images were acquired over 30min in list mode using a NanoScan PET/CT
(Mediso, Budapest, Hungary). Data were reconstructed using a 3D ordered-subset
expectation-maximization (OSEM) algorithm with eight iterations and six subsets
using corrections for decay, dead time, random events, attenuation and scatter, the
resulting image was isotropic with 300 mm voxels. Two sets of mCT were performed
immediately after mPET acquisition, using high and low zoom (67.1mm and
219mm between object and source, respectively). Images were obtained by helical
acquisition using a voltage, current and exposure time of 65 kVp, 123mA and
1,100ms. Images were reconstructed using a modiﬁed cone beam ﬁltered-back
projection method using a Butterworth ﬁlter producing a 22-mm and a 213-mm
isotropic data set. mPET and mCT data were co-registered using previously estab-
lished default shifts.
2D image processing and analysis. Two-dimensional image analysis was per-
formed using open-source software ImageJ/Fiji (http://ﬁji.sc) (NIH, Bethesda,
Maryland). Correlation between histology sections and autoradiography images
was achieved by using thresholded binary images of the different signals. In
addition, these thresholded images were ﬁltered with Gaussian blur (s¼ 20) and
thresholded again, to create segmentation masks that overcome the issue of
inherent resolution differences between histology and autoradiography signal
detection processes30.
Alizarin Red-stained calciﬁcation detection was performed using histogram-
based Otsu automated thresholding method31 and after Gaussian ﬁlter, it was
processed using Li thresholding32.
DAB-stained immunohistology sections were analysed using a colorimetric
thresholding method. While calciﬁcation stains provided excellent signal-intensity
to background ratio, this was not the case for immunohistochemistry. Therefore, a
colour combination that only detected the brown DAB stain was set as the manual
threshold value, irrespective of intensity. After Gaussian blurring, signal was
detected using Li auto-thresholding method.
Autoradiography images were resized to match the size of the histology images.
Then they were thresholded using Otsu method, Gaussian blurred and thresholded
using Li method.
All two-dimensional histology images were subjected to background subtraction
and histogram equalization.
Correlation between the various stained sections was accomplished using
multiple ImageJ/Fiji plug-ins. The position of specimens between individual images
was co-registred using TurboReg33 plug-in. Although tissues had been exposed to
acetone and alcohol ﬁxation protocols, we did not observe prominent contraction
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or shrinkage that would affect our data analysis. Images were then thresholded and
turned into binary data as described above. Pearson’s correlation coefﬁcient was
calculated using JACoP34 plug-in. Overlapping images of histological and
autoradiography signals were acquired using Co-localization Finder plug-in. The
overlapped images were processed further to determine PETþ /CT , PETþ /
CTþ and PET /CTþ regions in individual sections. Each colour corresponding
to one of the three detection modalities was separated out and quantiﬁed using
Analyze Particles command which counts the number of pixels in the binary
segmented mask.
3D image processing and analysis. 3D images after data reconstruction were
analysed using VivoQuant ver 1.23, (InviCRO, Boston, Massachusetts) software35.
For mPET/mCT initially the ﬁles were cropped to reduce ﬁle size and remove
experimental artifacts, such as the scanning panel and tube in which the carotid
was placed. Once an image containing only the signals associated with the carotid
was achieved, the colour intensities of both modalities were manually adjusted to
match histology/autoradiography signals as close as possible. After that, Distance/
Annotation function was selected and 5–8-mm linear transects were made across
slides in the transversal plane of carotids. The raw data were then downloaded and
graphs showing mCT densities and mPET units along the transect lines were later
reconstructed with Matlab (Mathworks, Natick, Massachusetts) software. To
quantify PETþ /CT , PETþ /CTþ and PET /CTþ regions on the 3D level,
3D ROI Tool function was selected. First, mPET data were thresholded using Otsu
method, to delineate the extent of PETþ signal. On the mCT plane we deﬁned
densities over 1000 Hounsﬁeld Units (HU) as calciﬁcations. To detect PETþ /
CTþ signal, we selected PETþ delineated 3D area and used Global thresholding
for Z1,000 HU of the mCT data in this area. To detect PET /CTþ areas, we
selected all remaining mCT data and applied theZ1,000 HU Global threshold. The
raw data containing information about the different modality regions was
downloaded and analysed with Microsoft Ofﬁce Excel (Microsoft, Redmond,
Washington).
Clinical PET/CT data were analysed by initially manually co-registering the
PET, CT and CT angiogram using bones as anatomical landmarks of the three
different modalities. Following this the images were zoomed in to the culprit plaque
and was cropped around this area. The division into PETþ /CT , PETþ /CTþ
and PET /CTþ regions was similar to as described for the mPET/mCT data. The
only exception was that CT and CT angiogram CTþ regions were also detected
using Otsu thresholding, to account for the inconsistencies of the amount of tracer
injected and imaging time after 18F-NaF injection.
Clinical PET/CT acquisition and dynamic analysis. Recruitment and scanning
for the in vivo aspect of this study took place following approval from the local
research ethics committee (National Health Service West of Scotland Research
Ethics Committee approval in Edinburgh: 12/WS/0227) and in accordance with the
Declaration of Helsinki. Patients with symptomatic carotid artery stenosis
(scheduled to undergo carotid endarterectomy)Z50% by NASCET criteria36 were
recruited from stroke and vascular surgery clinics at the Royal Inﬁrmary of
Edinburgh between January 2013 and April 2014. Exclusion criteria included a
modiﬁed Rankin score of Z3, insulin-dependent diabetes mellitus, women of
child-bearing age not receiving contraception, severe chronic kidney disease
(epidermal growth factor receptor o30mlmin 1 per 1.73m2), known iodine-
based contrast allergy, prior ipsilateral carotid intervention, prior neck irradiation
and inability to provide informed consent.
After giving their consent, patients underwent baseline clinical assessment
before undergoing dynamic or 18F-NaF PET/CT and CT carotid angiography with
the use of a hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen,
Germany).
For static 18F-NaF PET/CT, a target dose of 250MBq of 18F-NaF was
administered intravenously. Scanning took place 60min after injection. An
attenuation-correction CT scan (non-enhanced, low dose 120 kV, 50mAs) was
then performed followed by PET imaging covering two bed positions with the ﬁrst
upper bed centred over the carotid bifurcation in 3D mode for 15min per bed.
Analysis was undertaken as described above.
In ﬁve patients, 18F-NaF PET imaging was undertaken as a dynamic acquisition
with the PET scanner in list mode. Three of these subjects underwent arterial blood
sampling to directly assay the plasma arterial input function for model creation and
to assess 18F-NaF pharmacokinetics. An image-derived input function was utilized
for modelling in the two patients that did not undergo arterial cannulation and
sampling. The image-derived input function was generated by drawing regions of
interest in the proximal carotid artery lumen. After the ﬁtting of a soft neck collar
to minimize movement, subjects were placed in the PET/CT scanner with
intravenous and radial arterial catheters sited. An attenuation-correction CT scan
(non-enhanced, low dose 120 kV, 50mAs) was performed followed by PET
imaging with the single bed centred over the carotid bifurcation. A target dose of
250MBq of 18F-NaF was then administered intravenously at the same time as
scanning and blood sampling were initiated. Scanning took place for 75min. Real-
time whole-blood radioactivity was assayed using a calibrated Allogg ABSS V3
system (Allogg Technology, Mariefred, Sweden). In brief, whole arterial blood was
sampled through a narrow bore polytetraﬂuoroethylene tube using a roller pump at
a rate of 5mlmin 1 before being drawn through a shielded scintillation-based
detector. Counts were recorded using a data-logger. After 15min, the pump was
deactivated and 5ml samples were drawn intermittently for the remaining 60min.
Decay corrected whole blood and plasma radioactivity was then assayed using a
gamma counter. The fractional difference between whole blood and plasma
radioactivity was then calculated to adjust the data for the ﬁrst ﬁfteen min from the
Allogg device.
Following static and dynamic PET acquisitions, CT carotid angiograms were
also undertaken (Care Dose 4D, 120 kV, 145mA, rotation time 0.5 s, pitch 0.8).
Dynamic imaging data were reconstructed using the Siemens Ultra-HD
algorithm (time of ﬂight þ True X) with corrections applied for attenuation, dead
time, scatter and random coincidences. Imaging data were then parsed into the
following time bins as per Hawkins and Frost37,38 (12 10 s, 4 30 s, 12 240 s)
and analysed on a PMOD workstation (PMOD v3.408, PMOD Technologies Ltd.,
Zurich, Switzerland).
For analysis, the image data were ﬁrst reviewed for evidence of 18F-NaF uptake,
image quality and patient movement. The CT angiogram was scrutinized for
plaque presence, location and characteristics. The PET data were then resliced as
part of automated registration to the CT data. Volumes of interest were then
generated by drawing regions of interest on sequential axial slices on the registered
data sets. Volumes were drawn to separately incorporate internal carotid artery
plaque (where present) and a vertebral body. Vertebral data were obtained as a
comparator and also as a way of ensuring our data were commensurate with the
work of others. Tissue activity curves were then generated and assessed.
Dynamic analysis of ﬂuoride uptake in the bone has been well described. Since,
our data and that of others shows that over the time course of a typical 18F-PET/CT
scan ﬂuoride dissociation from calciﬁed tissue is undetectably slow, the Patlak
technique39,40 may be used to gain an estimate for the net ﬂux of ﬂuoride (Ki) into
a region of interest. Patlak derived Ki is calculated as follows:
Ct tð Þ
Cb tð Þ ¼ Ki
R t
0 Cb tð Þdt
Cb tð Þ þV ð1Þ
Ct(t) is the activity concentration of 18F-NaF at time t within the volume of interest,
Cb(t) is the blood activity concentration of 18F-NaF at time t and V relates to the
effective volume of distribution for 18F-NaF. The Patlak plot is obtained by plotting
Ct tð Þ
Cb tð Þ against Ki
R t
0
Cb tð Þdt
Cb tð Þ and calculating the slope of the regression line as given in
equation (1).
This method has been extensively described and compared with multi-
compartmental modelling with both techniques showing good agreement. To
ensure equilibrium between the plasma and compartments had been achieved, we
only plotted the data from 10min onwards as described by Frost38. Patlak plots
were generated for all carotid plaques and vertebra (see Supplementary Fig. 2 for a
representative example and Supplementary Table 1). We also plotted directly
measured plasma activity curves for illustration of the pharmacokinetics of
18F-NaF (for a representative example, see Supplementary Fig. 3).
Data analysis. Numerical data analysis was performed using Microsoft Ofﬁce
Excel (Microsoft, Redmond, Washington), Matlab (Mathworks, Natick, Massa-
chusetts) and Prism (GraphPad, San Diego, California) softwares. Written text was
produced using Microsoft Ofﬁce Word (Microsoft, Redmond, Washington) and
ﬁgures were made using Adobe Illustrator CS5 (Adobe Systems, San Jose,
California).
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